At the BIO 2026 conference, FDA leadership confronted two pressing issues: internal workforce attrition and intensifying competition from China in drug development. The panel included acting directors of the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, as well as the acting chief of staff.
Workforce losses at the agency have raised concerns about review timelines and regulatory capacity. The acting directors acknowledged these challenges but did not disclose specific numbers or hiring targets, emphasizing ongoing efforts to retain talent and maintain operational efficiency.
China's growing role in drug development was a major theme. Panelists noted that Chinese firms are accelerating their pipelines, leveraging domestic incentives and a large patient pool for trials. The FDA signaled a need to balance global collaboration with safeguarding U.S. innovation and regulatory standards.
No specific drugs or clinical data were discussed during the session. The discussion remained strategic, focusing on policy directions rather than individual approvals or trial results. Investors and analysts are watching for concrete actions in the coming months.
A countervailing view: some industry observers argue that workforce shortages, while real, are being addressed through targeted hiring and process reforms, and that China’s competition may spur beneficial collaboration rather than posing a direct threat.